Mesoblast Ltd lost $0.04 per diluted share in fiscal year 2026. The change from the prior fiscal year is not meaningful, because that figure was zero or negative. The table below carries 11 fiscal years, from 2016 to 2026, and the quarters Mesoblast Ltd has filed alongside them.
FY2026 annual
EPS (Diluted)-$0.04
YoYn/m
5Y CAGRn/m
10Y CAGRn/m
Source SEC Filings (20-F/6-K)Latest period FY2026, ended Jun 30, 2026ReportedCurrency USD
Annual figures, oldest first. Point at a bar to read its period.
MEOBF EPS (Diluted) by Fiscal Year
Figures are as reported in USD. Each change compares the year with the year before it, and each column links to the filing it was taken from.
Diluted earnings per share divides net income by the share count the company would have if every option and convertible security were exercised, which is the more conservative of the two per-share figures a filer reports.
Mesoblast Ltd lost $0.04 per diluted share in fiscal year 2026.
Mesoblast Ltd (MEOBF) reported a loss of $0.08 per diluted share in fiscal year 2025 and a loss of $0.04 per diluted share in fiscal year 2026. A growth rate is not meaningful here, because the earlier figure was zero or negative.
Across the 11 fiscal years this page covers, Mesoblast Ltd (MEOBF) diluted earnings per share went from -$0.01 in fiscal year 2016 to -$0.04 in fiscal year 2026.
Diluted earnings per share divides net income by the share count the company would have if every option and convertible security were exercised, which is the more conservative of the two per-share figures a filer reports. This page lists what Mesoblast Ltd (MEOBF) reported on that line in every period on record.
